Results 151 to 160 of about 73,788 (259)

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, Volume 73, Issue 8, August 2026.
ABSTRACT Background Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) is assessed by cell counting and cytomorphology from cerebrospinal fluid (CSF) and is used for treatment stratification worldwide. The ratio of “CNS2” patients in clinical trials ranges from 3% to 40%, with unclear prognostic significance ...
Laura Almási   +14 more
wiley   +1 more source

Early identification of vascular cognitive impairment from a multimodal perspective: a combined diagnosis from targeted cognitive assessments, imaging biomarkers, and molecular fluid biomarkers to ecological behavioral characteristics

open access: yesAlzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract Vascular cognitive impairment (VCI), the second leading cause of dementia, is characterized by heterogeneous pathophysiology and a potentially reversible early phase, underscoring the need for timely identification. This review synthesizes advances across four complementary domains – targeted cognitive assessments, imaging biomarkers ...
Wenqi Song   +8 more
wiley   +1 more source

Engagement of understudied populations as community change: The South Texas ADRC model

open access: yesAlzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract Many populations experiencing the highest burdens of Alzheimer's disease and related dementias remain understudied, in part because traditional recruitment and retention models are insufficient to support sustained engagement. The Outreach, Recruitment, and Engagement Core (OREC) of the South Texas Alzheimer's Disease Research Center ...
Gladys E. Maestre   +34 more
wiley   +1 more source

CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults

open access: yesAlzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Blood–brain barrier (BBB) dysfunction is an early feature of Alzheimer's disease (AD). Fibrinogen represents a sensitive marker of BBB leakage, but whether it modifies longitudinal tau progression in cognitively unimpaired (CU) individuals remains unknown.
Christos Panagiotis Lisgaras   +21 more
wiley   +1 more source

Long‐term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study

open access: yesAlzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION ABvac40 is an active immunotherapy targeting Aβ40, the main component of cerebrovascular deposition in Alzheimer's disease (AD). A 24‐month randomized, placebo‐controlled phase 2 study (Part A) showed favorable safety and robust immunogenicity, with exploratory signals of clinical efficacy.
María Pascual‐Lucas   +15 more
wiley   +1 more source

Multicentre study of the role of lumbar puncture in the diagnosis of spontaneous subarachnoid haemorrhage. [PDF]

open access: yesActa Neurochir (Wien)
Thompson D   +7 more
europepmc   +1 more source

Cerebrospinal Fluid Amyloid‐β Biomarkers Predict Future Hemorrhage in Patients with Cerebral Amyloid Angiopathy

open access: yesAnnals of Neurology, Volume 100, Issue 2, Page 391-399, August 2026.
Objective Accurately predicting future hemorrhagic events in patients with cerebral amyloid angiopathy (CAA) remains a major clinical challenge. It is unknown whether cerebrospinal fluid (CSF) biomarkers of amyloid‐beta (Aβ) pathology are associated with increased hemorrhage risk in this population.
Philipp Arndt   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy